Q3 results today: Maruti, Sun Pharma, Dabur among 113 companies to announce earnings

Wednesday will be a results heavy day as 113 BSE listed companies will be announcing their December quarter earnings. However, one of the most anticipated results from the auto segment - Maruti Suzuki India (MSIL) will be looked upon closely. Sun Pharmaceuticals will be another Nifty company which will be declaring its Q3FY24 earnings today.

Among other important results will be those by Ajanta Pharma, Ambuja Cements, Atul Auto, Bank of Baroda, Dabur India, Data Patterns, DB Realty, IDFC, Jindal Steel, Jyothy Labs, Kalyan Jewellers, Mankind Pharma, PVR Inox, Suzlon Energy and Shree Cement.

On Tuesday, 95 companies including Larsen & Toubro (L&T), Bajaj Finserv and Dr Reddy's Laboratories announced their October-December quarter earnings.


Here's what to expect from Maruti Suzuki and Sun Pharma earnings

Maruti Q3 results

India's largest carmaker Maruti Suzuki is likely to report healthy revenue growth in the quarter ended December, supported by higher volumes and an increase in average selling prices (ASPs). The company will report its third-quarter earnings on January 31.

Operating revenue for the third quarter is expected to rise 15% year-on-year (YoY), according to an average estimate of four brokerages. Meanwhile, profit for the same period is seen rising up to 34% YoY.

Maruti Suzuki has already reported 8% growth in its volumes for the October-December period.

Read More: Maruti Suzuki Q3 Results Preview: Revenue to grow in double digits on higher volumes

Sun Pharma Q3 results

Sun Pharmaceutical Industries Ltd is expected to report single-digit growth in revenue for the quarter ended December amid moderate sales in the US and India. Higher spending towards research and development (R&D) may constrain growth in the operating profit, said analysts.

The drugmaker is expected to report a nearly 8% year-on-year (YoY) growth in consolidated net profit to Rs 2,329 crore, according to the average of estimates given by six brokerage firms.

Read More: Sun Pharma Q3 preview: Consolidated PAT may rise 8% YoY amid moderate revenue growth

(You can now subscribe to our ETMarkets WhatsApp channel)

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)